What is HC Wainwright's Estimate for DYN Q2 Earnings?

Key Points

• HC Wainwright forecasts Dyne Therapeutics’ Q2 2027 loss at $1.00 per share; it also estimates losses of $0.92 in Q3 and $0.62 in Q4 2027, and earnings of $0.84 per share in FY2030.
• The firm maintains a Buy rating and $32 price target. Analysts overall rate DYN “Moderate Buy,” with a consensus price target of $31.29.
• Dyne reported a Q3 loss of $1.06 per share, wider than the $0.91 loss analysts expected. The company’s z-rostudirsen application is under FDA priority review, with a target decision date of January 21, 2027.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - HC Wainwright issued their Q2 2027 EPS estimates for Dyne Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings per share of ($1.00) for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 price target on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Dyne Therapeutics' Q3 2027 earnings at ($0.92) EPS, Q4 2027 earnings at ($0.62) EPS and FY2030 earnings at $0.84 EPS.

A number of other research analysts also recently issued reports on the stock. Piper Sandler restated an "overweight" rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. Wall Street Zen lowered shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Cantor Fitzgerald reiterated a "buy" rating on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Stifel Nicolaus set a $37.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from a "neutral" rating to an "underweight" rating and dropped their price target for the stock from $17.00 to $10.00 in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $31.29.

Dyne Therapeutics Stock Performance

DYN stock opened at $18.07 on Monday. The business has a fifty day moving average of $17.70 and a 200-day moving average of $19.33. The company has a market cap of $3.39 billion, a P/E ratio of -4.98 and a beta of 1.22. Dyne Therapeutics has a twelve month low of $14.00 and a twelve month high of $27.31. The company has a quick ratio of 12.99, a current ratio of 12.99 and a debt-to-equity ratio of 0.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.15). During the same quarter in the previous year, the company posted ($0.76) earnings per share.

Insider Buying and Selling

In other news, CEO John Cox sold 5,658 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the transaction, the chief executive officer directly owned 357,507 shares in the company, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 3,745 shares of the business's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the transaction, the insider owned 163,854 shares of the company's stock, valued at $3,989,844.90. The trade was a 2.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 2,598,706 shares of company stock worth $65,432,671. Company insiders own 9.46% of the company's stock.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Dyne Therapeutics during the second quarter valued at approximately $275,500,000. Jupiter Topco LLC bought a new stake in Dyne Therapeutics in the second quarter valued at approximately $266,634,000. Bank of America Corp DE bought a new stake in Dyne Therapeutics in the second quarter valued at approximately $49,604,000. Palo Alto Investors LP bought a new stake in Dyne Therapeutics in the second quarter valued at approximately $36,591,441. Finally, Perceptive Advisors LLC raised its holdings in Dyne Therapeutics by 34.2% in the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company's stock worth $84,646,000 after purchasing an additional 1,189,895 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: The FDA is conducting a priority review of Dyne’s biologics license application for z-rostudirsen, its exon 51 Duchenne muscular dystrophy (DMD) candidate. The FDA’s target action date is January 21, 2027, providing a defined near-term regulatory catalyst. Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Management said its cash runway extends into the second quarter of 2028, providing funding visibility for ongoing development. The company also reported progress in its DMD and DM1 programs ahead of planned 2027 milestones. Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
• Neutral Sentiment: A valuation commentary raised the possibility that DYN is undervalued, citing its pipeline and the FDA priority review, but this is an opinion rather than a new company development. Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
• Negative Sentiment: Third-quarter EPS was a loss of $1.06, wider than analysts’ expected $0.91 loss and the $0.76 loss a year earlier. Reports attributed the increased loss to higher research and development spending, highlighting rising development costs. Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company's programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.